The Burns Unit in Copenhagen. 10. Antibiotic sensitivity of Staphylococcus aureus isolated from burns.
D001414:Bacitracin / Q000627:therapeutic use; D002056:Burns / Q000150:complications / Q000382:microbiology*; D002701:Chloramphenicol / Q000627:therapeutic use; D003428:Cross Infection; D004917:Erythromycin / Q000627:therapeutic use; D005672:Fusidic Acid / Q000627:therapeutic use; D006801:Humans; D008712:Methicillin / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009355:Neomycin / Q000627:therapeutic use; D009666:Nose / Q000382:microbiology; D009675:Novobiocin / Q000627:therapeutic use; D010403:Penicillin Resistance; D010406:Penicillins / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000302:isolation & purification; D013307:Streptomycin / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use
D010406:Penicillins; D001414:Bacitracin; D009675:Novobiocin; D005672:Fusidic Acid; D004917:Erythromycin; D002701:Chloramphenicol; D013752:Tetracycline; D009355:Neomycin; D008712:Methicillin; D013307:Streptomycin